Giacobini E, Cuello AC, Fisher A (2022) <br />Reimagining cholinergic therapy for Alzheimer's disease<br /><i>Brain</i> <b>145</b>: 2250<br /><br />Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR (2019) <br />Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia<br /><i>Pharmacoepidemiol Drug Safety</i> <b>28</b>: 1067<br /><br />Fisher A, Carney G, Bassett K, Dormuth CR (2017) <br />Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching<br /><i>Drugs & Aging</i> <b>34</b>: 221<br /><br />Fisher A, Carney G, Bassett K, Chappell NL (2016) <br />Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation<br /><i>Value Health</i> <b>19</b>: 688<br /><br />Welt T, Kulic L, Hoey SE, McAfoose J, Spani C, Chadha AS, Fisher A, Nitsch RM (2015) <br />Acute Effects of Muscarinic M1 Receptor Modulation on AbetaPP Metabolism and Amyloid-beta Levels in vivo: A Microdialysis Study<br /><i>J Alzheimers Dis</i> <b>46</b>: 971<br /><br />Fisher A (2012) <br />Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease<br /><i>Journal of Neurochemistry</i> <b>120 Suppl 1</b>: 22<br /><br />Alfa Cisse M, Louis K, Braun U, Mari B, Leitges M, Slack BE, Fisher A, Auberger P, Checler F, Vincent B (2008) <br />Isoform-specific contribution of protein kinase C to prion processing<br /><i>Molecular & Cellular Neurosciences</i> <b>39</b>: 400<br /><br />Fisher A (2008) <br />Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease<br /><i>Neurotherapeutics</i> <b>5</b>: 433<br /><br />Alfa Cisse M, Sunyach C, Slack BE, Fisher A, Vincent B, Checler F (2007) <br />M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity<br /><i>Journal of Neuroscience</i> <b>27</b>: 4083<br /><br />Madan A, Fisher A, Jin L, Chapman D, Bozigian HP (2007) <br />In vitro metabolism of indiplon and an assessment of its drug interaction potential<br /><i>Xenobiotica</i> <b>37</b>: 736<br /><br />Fisher A, Brandeis R, Pittel Z, Haring R, Sparks L, Beach TG, Bons N, Maestre-Frances N, Bar-Ner N, Kliger-Spatz M, Natan N, Marcovitch I, Hartmann T (2004) <br />Poster (46) Major hallmarks in alzheimer's disease (ad) can beneficially be modulated by M1 muscarinic agonists - an added value vs. cholinesterase inhibitors<br /><i>In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects</i> <b> (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina</b>: 345<br /><br />Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003) <br />M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy<br /><i>Journal of Molecular Neuroscience</i> <b>20</b>: 349<br /><br />O'Neill J, Siembieda DW, Crawford KC, Halgren E, Fisher A, Fitten LJ (2003) <br />Reduction in distractibility with AF102B and THA in the macaque<br /><i>Pharmacol Biochem Behav</i> <b>76</b>: 301<br /><br />Fisher A (2000) <br />Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists<br /><i>Japanese Journal of Pharmacology</i> <b>84</b>: 101<br /><br />Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z (2000) <br />M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives<br /><i>Annals of the New York Academy of Sciences</i> <b>920</b>: 315<br /><br />Fitten LJ, Ortiz F, Siembieda DW, O'Neill J, Halgren E, Fisher A (1999) <br />Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque<br /><i>J Neuropsychiatry Clin Neurosci</i> <b>11</b>: 79<br /><br />Genis I, Fisher A, Michaelson DM (1999) <br />Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment<br /><i>Journal of Neurochemistry</i> <b>72</b>: 206<br /><br />O'Neill J, Fitten LJ, Siembieda DW, Crawford KC, Halgren E, Fisher A, Refai D (1999) <br />Divided attention-enhancing effects of AF102B and THA in aging monkeys<br /><i>Psychopharmacology (Berl)</i> <b>143</b>: 123<br /><br />Pittel Z, Fisher A, Eshhar N, Haring R, Heldman E (1999) <br />Poster: Effect of muscarinic stimulation on beta-amyloid precursor protein processing in rat brain and primary cultures<br /><i>Life Sciences</i> <b>64</b>: 572<br /><br />Chapman S, Fisher A, Weinstock M, Brandies R, Shohami E, Michaelson DM (1998) <br />The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice<br /><i>Journal de Physiologie Paris</i> <b>92</b>: 299<br /><br />Fisher A, Brandeis R, Haring R, Eshhar N, Heldman E, Karton Y, Eisenberg O, Meshulam H, Marciano D, Bar-Ner N, Pittel Z (1998) <br />Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis<br /><i>Journal de Physiologie (Paris)</i> <b>92</b>: 337<br /><br />Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM (1998) <br />M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice<br /><i>Journal of Neurochemistry</i> <b>70</b>: 1991<br /><br />O'Neill J, Fitten LJ, Siembieda D, Halgren E, Kim E, Fisher A, Perryman K (1998) <br />Effects of AF102B and tacrine on delayed match-to-sample in monkeys<br /><i>Prog Neuropsychopharmacol Biological Psychiatry</i> <b>22</b>: 665<br /><br />Haring R, Eshhar N, Heldman E, Marciano D, Kloog Y, Fisher A (1997) <br />Poster: An M1 selective agonist AF102b, as a potential drug in treatment of Alzheimer's disease: Biochemical and pharmacological properties<br /><i>Life Sciences</i> <b>60</b>: 1183<br /><br />Danenberg HD, Haring R, Fisher A, Pittel Z, Gurwitz D, Heldman E (1996) <br />Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein<br /><i>Life Sciences</i> <b>59</b>: 1651<br /><br />Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD (1996) <br />M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update<br /><i>Annals of the New York Academy of Sciences</i> <b>777</b>: 189<br /><br />Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996) <br />Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum<br /><i>Brain Research</i> <b>742</b>: 299<br /><br />Danenberg HD, Haring R, Heldman E, Gurwitz D, Ben-Nathan D, Pittel Z, Zuckerman A, Fisher A (1995) <br />Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells<br /><i>Annals of the New York Academy of Sciences</i> <b>774</b>: 300<br /><br />Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A (1994) <br />Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands<br /><i>European Journal of Pharmacology</i> <b>267</b>: 21<br /><br />Fisher A, Heldman E, Gurwitz D, Haring R, Barak D, Meshulam H, Marciano D, Brandeis R, Pittel Z, Segal M, et al. (1993) <br />Selective signaling via unique M1 muscarinic agonists<br /><i>Annals of the New York Academy of Sciences</i> <b>695</b>: 300<br /><br />Fisher A, Karton Y, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Pittel Z, Segall Y, Marciano D, et al. (1993) <br />Progress in medicinal chemistry of novel selective muscarinic agonists<br /><i>Drug Des Discov</i> <b>9</b>: 221<br /><br />Pittel Z, Fisher A, Vogel Z, Heldman E (1993) <br />Poster: Transmembrane signaling of M1 muscarinic receptors in the rat brain and cell cultures<br /><i>Life Sciences</i> <b>52(5-6)</b>: 565<br /><br />Riekkinen P, Jr., Riekkinen M, Fisher A, Ekonsalo T, Sirvio J (1993) <br />Effects of muscarinic receptor agonists and anticholinesterase drugs on high voltage spindles and slow waves<br /><i>European Journal of Pharmacology</i> <b>240</b>: 1<br /><br />Pittel Z, Cohen S, Fisher A, Heldman E (1992) <br />Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes<br /><i>Brain Research</i> <b>586</b>: 148<br /><br />Segal M, Fisher A (1992) <br />AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices<br /><i>European Journal of Pharmacology</i> <b>220</b>: 103<br /><br />Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E (1991) <br />(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>257</b>: 392<br /><br />Potter LT, Ballesteros LA, Bichajian LH, Ferrendelli CA, Fisher A, Hanchett HE, Zhang R (1991) <br />Evidence of paired M2 muscarinic receptors<br /><i>Molecular Pharmacology</i> <b>39</b>: 211<br /><br />Mochida S, Mizobe F, Fisher A, Kawanishi G, Kobayashi H (1988) <br />Dual synaptic effects of activating M1-muscarinic receptors, in superior cervical ganglia of rabbits<br /><i>Brain Research</i> <b>455</b>: 9<br /><br />Sandberg K, Schnaar RL, McKinney M, Hanin I, Fisher A, Coyle JT (1985) <br />AF64A: an active site directed irreversible inhibitor of choline acetyltransferase<br /><i>Journal of Neurochemistry</i> <b>44</b>: 439<br /><br />Mantione CR, Fisher A, Hanin I (1984) <br />Possible mechanisms involved in the presynaptic cholinotoxicity due to ethylcholine aziridinium (AF64A) in vivo<br /><i>Life Sciences</i> <b>35</b>: 33<br /><br />Sandberg K, Hanin I, Fisher A, Coyle JT (1984) <br />Selective cholinergic neurotoxin: AF64A's effects in rat striatum<br /><i>Brain Research</i> <b>293</b>: 49<br /><br />Szerdahelyi P, Kasa P, Fisher A, Hanin I (1984) <br />Effects of the cholinotoxin, AF64A, on neuronal trace-metal distribution in the rat hippocampus and neocortex<br /><i>Histochemistry</i> <b>81</b>: 497<br /><br />Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A, Hanin I (1984) <br />AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat<br /><i>Brain Research</i> <b>321</b>: 91<br /><br />Mantione CR, De Groat WC, Fisher A, Hanin I (1983) <br />Selective inhibition of peripheral cholinergic transmission in the cat produced by AF64A<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>225</b>: 616<br /><br />Mantione CR, Zigmond MJ, Fisher A, Hanin I (1983) <br />Selective presynaptic cholinergic neurotoxicity following intrahippocampal AF64A injection in rats<br /><i>Journal of Neurochemistry</i> <b>41</b>: 251<br /><br />Fisher A, Mantione CR, Abraham DJ, Hanin I (1982) <br />Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>222</b>: 140<br /><br />Fisher A, Hanin I (1980) <br />Choline analogs as potential tools in developing selective animal models of central cholinergic hypofunction<br /><i>Life Sciences</i> <b>27</b>: 1615<br /><br />Fisher A, Abraham S, Lachman C, Lass Y, Akselrod S, Akerman E, Cohen S (1980) <br />Does rigidity in structure of muscarinic agonists and antagonists reflect drug specificity?<br /><i>Monogr Neural Sci</i> <b>7</b>: 41<br /><br />Lass Y, Akselrod S, Gavish B, Cohen S, Fisher A (1979) <br />Offset rate of action of muscarinic antagonists depends on their structural flexibility<br /><i>Experientia</i> <b>35</b>: 650<br /><br />Fisher A, Grunfeld Y, Weinstock M, Gitter S, Cohen S (1976) <br />A study of muscarinic receptor heterogeneity with weak antagonists<br /><i>European Journal of Pharmacology</i> <b>38</b>: 131<br /><br />